Immuneering Corporation announced positive updated overall survival and safety data from its ongoing Phase 2a clinical trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer patients. With over 13 months median follow-up, the 12-month overall survival rate was reported at 64%, nearly double that of the benchmark from the pivotal study of the standard of care. Median overall survival has not yet been reached as of the data cutoff. Immuneering plans to report updated survival data from over 50 patients treated with atebimetinib + mGnP in the first half of 2026, and updated circulating tumor DNA data in the second quarter of 2026. The company anticipates dosing the first patient in its pivotal Phase 3 MAPKeeper 301 trial in mid-2026. Results from the Phase 2a trial have already been presented, and additional data will be presented at future scientific meetings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621626-en) on January 07, 2026, and is solely responsible for the information contained therein.